TP53 and cancer: Intriguingly, however a recent study showed that depletion by CRISPR/Cas9 of 12 distinct p53 mutants, known for their reported GOF effects displayed no discernible effects on the proliferation and response to chemotherapeutic agents in 15 human cancer cell lines and organoids, nor any effect in the capability of these cell lines to growth in vivo and colonize mouse organs [60].